More About Office of Technology Development Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.

SK-MEL-2: Human Melanoma Cell Line (ATCC HTB-68)

SK 779

Description

SK-MEL-2 is one of a series of melanoma cell lines established from patient-derived tumor samples. This cell line expresses wildtype B-Raf and mutant N-Ras (Q61R).

Source

This cell line was established in 1972 from a metastatic site on the thigh of a 60-year-old Caucasian male with malignant melanoma.

Inventors

  • Lloyd J. Old, MD, former William E. Snee Chair in Cancer Immunology, Memorial Sloan Kettering; former Director, New York Branch, Ludwig Institute for Cancer Research
  • Germain Trempe, formerly at Sloan Kettering Institute, Memorial Sloan Kettering

Key References

  • Fogh J et al. (1977) One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. Journal of the National Cancer Institute 59: 221-226 (PubMed ID: 327080)
  • Xing F et al. (2012) Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E) BRAF. Oncogene 31(4):446-457 (PubMed ID: 21725359)

Licensing Information

This cell line may be licensed nonexclusively for research or commercial purposes.

For internal research purposes by a commercial entity: Utilize MSK’s Express License, available here. In order to streamline and expedite the licensing of select MSK cell lines, the terms of this non-exclusive license are non-negotiable. Please note: This license is only available for select cell lines, including this one.

To proceed, please download this contract, fill in all relevant fields, and email a scanned version to Alexandra Buga at bugaa@mskcc.org.  Once this license has been executed by MSK, you will receive a signed copy and invoice, and can then place your order with ATCC.

For licensing requests for a commercial purpose:  Contact Alexandra Buga, MS, MBA, Licensing Associate, Office of Technology Development, MSK, 646-888-1078, bugaa@mskcc.org.

For non-licensing requests from academic-research institutions: Contact Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody & Bioresource Core Facility, MSK, 646-888-2354, weisgarf@mskcc.org

Stage of Development

Ready to use

Indications